Trial Profile
Phase II study of irinotecan plus cisplatin followed by amrubicin in patients with extensive disease small-cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2016
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Cisplatin (Primary) ; Irinotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 04 Jun 2009 New trial record.